Enzo Biochem, Inc. (NYSE:ENZ) Sees Significant Decline in Short Interest

Enzo Biochem, Inc. (NYSE:ENZ) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 433,000 shares, a decline of 9.3% from the October 31st total of 477,500 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average trading volume of 86,700 shares, the days-to-cover ratio is presently 5.0 days.

Enzo Biochem Price Performance

NYSE:ENZ opened at $1.08 on Monday. Enzo Biochem has a 1-year low of $0.93 and a 1-year high of $1.50. The business’s fifty day moving average price is $1.11 and its 200 day moving average price is $1.11.

Enzo Biochem Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 15th will be given a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 37.04%. The ex-dividend date is Friday, November 15th.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Enzo Biochem in a research note on Sunday. They issued a “hold” rating for the company.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd boosted its stake in shares of Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after buying an additional 13,735 shares during the period. BBR Partners LLC purchased a new stake in shares of Enzo Biochem during the third quarter worth $112,000. Geode Capital Management LLC boosted its position in Enzo Biochem by 3.3% during the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares in the last quarter. 36.90% of the stock is owned by hedge funds and other institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.